Among the quiet vulnerabilities of pregnancy, a familiar and inexpensive medication has revealed an unexpected gift: for women whose metabolisms place them at higher risk, metformin appears to meaningfully delay premature birth. A Monash University analysis of nearly 2,300 pregnancies across seven trials found a 35 percent reduction in early delivery before 37 weeks—a discovery that, while requiring further confirmation, places an old drug in a new and hopeful light for the one in five Australian pregnancies touched by metabolic risk.
Metformin reduces preterm birth risk by 35% in high-risk pregnancies
Preterm birth affects over 26,000 Australian babies annually, placing infants at risk of respiratory distress, developmental complications, and prolonged neonatal intensive care stays.
An extra 11 days in utero can reshape a newborn's survival.
Mark
So metformin didn't actually prevent gestational diabetes—the thing it's supposed to help with. How do you explain a 35 percent reduction in preterm birth if it didn't do what you expected?
Mimi
That's the puzzle, isn't it? Metformin works on insulin sensitivity and blood sugar control. Even if it doesn't prevent gestational diabetes from developing, it's still improving how the body handles glucose and metabolic stress. That underlying improvement seems to protect against premature labour, even if it doesn't stop the diabetes itself.
Mark
And the fact that it halved births before 34 weeks—that's the really critical window, right? Those are the babies at highest risk.
Mimi
Exactly. Thirty-four weeks is when organ systems are still developing rapidly. An extra two weeks in utero can mean the difference between a baby needing weeks in intensive care and one that can breathe on its own. Eleven days average extension is real.
Mark
Why do you think earlier studies missed this? They had access to metformin data too.
Mimi
They were smaller, isolated. You need thousands of pregnancies to see a 35 percent reduction clearly. And you need to account for all the variables—age, weight, glucose levels, when women started the drug. Pooling data from seven trials let them do that in a way no single study could.
Mark
What's the next question? What do researchers actually need to know now?
Mimi
When to start it, for one. Early pregnancy? Later? And whether the benefit holds across different populations. This was high-risk metabolic pregnancies. Does it work the same way for everyone? That's what the larger collaboration is trying to answer.
The Pulse
- More than 26,000 Australian babies are born prematurely each year, facing respiratory crises, developmental setbacks, and weeks or months in neonatal intensive care—a burden that researchers have long sought ways to reduce.
- Women with higher body weight, insulin resistance, or polycystic ovary syndrome carry a compounded vulnerability during pregnancy, and existing interventions have offered limited protection against early labour.
- A pooled analysis of seven randomized trials found metformin cut preterm births before 37 weeks by 35 percent and halved the rate of very early births before 34 weeks, extending pregnancies by an average of 11 days even among those who delivered early.
- Crucially, metformin did not affect birth weight, blood pressure, pre-eclampsia, or caesarean rates—narrowing its benefit to the specific and significant question of gestational timing.
- Researchers caution that dedicated trials targeting preterm birth prevention are still needed, and the optimal window for beginning metformin treatment during pregnancy remains an open question under active investigation.
Among the quiet vulnerabilities of pregnancy, a familiar and inexpensive medication has revealed an unexpected gift: for women whose metabolisms place them at higher risk, metformin appears to meaningfully delay premature birth. A Monash University analysis of nearly 2,300 pregnancies across seven trials found a 35 percent reduction in early delivery before 37 weeks—a discovery that, while requiring further confirmation, places an old drug in a new and hopeful light for the one in five Australian pregnancies touched by metabolic risk.
Researchers at Monash University have uncovered a striking secondary benefit of metformin—a widely used, low-cost diabetes medication—in pregnant women facing metabolic challenges. Drawing on individual patient data from seven randomized, placebo-controlled trials encompassing 2,297 pregnancies, the team found that metformin significantly reduced the likelihood of premature birth, even though it did not prevent gestational diabetes as originally hoped.
The study focused on women with higher body weight, insulin resistance, or polycystic ovary syndrome—conditions that now touch roughly one in five pregnancies in Australia and can increase the risk of early labour. Women taking metformin were 35 percent less likely to deliver before 37 weeks than those on placebo. More strikingly, the rate of births before 34 weeks was halved, falling from 4.4 percent to 2.2 percent. For those who did deliver prematurely, metformin extended pregnancy by an average of 11 days—a clinically meaningful margin when infant survival and health hang in the balance.
Preterm birth remains one of the leading causes of newborn death and serious illness, with over 26,000 Australian babies arriving early each year. The medication's protective effect appears tied to its ability to improve insulin sensitivity and reduce metabolic stress, though it showed no influence on birth weight, blood pressure, pre-eclampsia, or mode of delivery.
Associate Professor Aya Mousa and senior author Professor Helena Teede led the work through Monash's Centre for Health Research & Implementation, emphasizing that pooling original data across multiple trials allowed for a more rigorous analysis than any single study could achieve. The research forms part of a broader international collaboration now examining long-term outcomes of metformin exposure during pregnancy and the question of when treatment should ideally begin. Researchers are clear that these findings, while significant, await confirmation through trials designed specifically around preterm birth prevention.
Researchers at Monash University have found that metformin, an inexpensive oral medication commonly prescribed to manage blood sugar in diabetes patients, can significantly reduce the risk of premature birth in pregnant women facing metabolic challenges. The discovery emerged from a comprehensive analysis of seven randomized, placebo-controlled trials involving 2,297 pregnancies, published in the New England Journal of Medicine Evidence.
The study focused on women at high metabolic risk—those carrying extra weight, experiencing insulin resistance, or living with polycystic ovary syndrome. These conditions create vulnerability during pregnancy. Gestational diabetes, characterized by elevated blood sugar that develops during pregnancy, now affects roughly one in five pregnant women in Australia and can trigger premature labour in severe cases. Researchers wanted to know whether metformin could prevent gestational diabetes and protect against other adverse pregnancy outcomes, particularly early delivery.
The results showed metformin did not prevent gestational diabetes overall. But it offered striking protection against premature birth. Women taking metformin had 35 percent lower odds of delivering before 37 weeks compared with those receiving placebo. The benefit extended further: the medication halved the rate of births before 34 weeks, dropping it to 2.2 percent from 4.4 percent in the placebo group. For women who did deliver prematurely despite treatment, metformin extended pregnancy by an average of 11 days—a clinically meaningful buffer that can improve infant outcomes.
Preterm birth remains a leading cause of death and serious illness for newborns and mothers. In Australia alone, more than 26,000 babies—roughly 8 percent of all births—arrive prematurely each year. These infants face respiratory distress, developmental complications, and often require extended stays in neonatal intensive care units. The medication works by helping the body use insulin more effectively, lowering blood sugar levels and reducing metabolic stress during pregnancy.
Associate Professor Aya Mousa, who led the research at Monash's Centre for Health Research & Implementation, emphasized that the findings warrant careful follow-up. The analysis combined individual patient data from multiple trials, allowing researchers to account for differences in age, body mass index, blood glucose levels, and when treatment began—a methodological strength that earlier isolated studies lacked. Metformin did not affect other pregnancy outcomes like birth weight, high blood pressure, pre-eclampsia, induction of labour, or Caesarean section rates.
The work forms part of the larger Metformin in Pregnancy Study, an international collaboration pooling data from thousands of women across multiple randomized trials. Senior author Professor Helena Teede, director of the research centre and an endocrinologist at Monash Health, noted that bringing together original data from diverse trials gave researchers a clearer picture of metformin's effects than any single study could provide. The collaboration is now investigating long-term outcomes of metformin exposure during pregnancy and exploring questions about optimal timing for starting the medication. Researchers acknowledge that these findings, while significant, need confirmation through trials specifically designed to investigate preterm birth prevention.
Notable Quotes
Women taking metformin had 35 percent lower odds of giving birth prematurely compared with those receiving placebo, with births before 34 weeks halved to 2.2 percent from 4.4 percent.— Associate Professor Aya Mousa, Monash University
By bringing together original data from thousands of women across international trials, researchers could examine individual participants and account for differences such as age, body mass index, and blood glucose levels, giving a clearer picture of metformin's effects during pregnancy.— Professor Helena Teede, Monash Centre for Health Research & Implementation
Want the full story?
Read the original at News-Medical ↗
Science & Space